Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting

Presentation Details Statistically Significant Clinical Results for SB-509 in Development for Treatment of Diabetic Neuropathy

CHICAGO, June 22, 2007 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of encouraging Phase 1 clinical data from its ZFP Therapeutic(TM) program at the 67th Scientific Sessions of the American Diabetes Association (ADA). As disclosed in an oral presentation entitled, "Improved Neurologic Exam and Nerve Conduction Velocities in Diabetic Neuropathy Patients Treated with Vascular Endothelial Growth Factor (VEGF) Zinc Finger Protein Activator (SB-509)," results of Sangamo's Phase 1b clinical trial demonstrated statistically significant improvements in subjects with diabetic neuropathy. SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). Sangamo is currently evaluating SB-509 in two ongoing Phase 2 clinical trials for the treatment of diabetic neuropathy.

"We are very excited by the significant improvements that we observed in several measurements of nerve health in subjects with mild to moderate diabetic neuropathy over six months after a single administration of SB-509," commented the presenter, Mark Kipnes, M.D., lead investigator on the Phase 1 trial and an endocrinologist at the Diabetes and Glandular Disease Clinic, San Antonio, Texas. "The data obtained in this clinical trial demonstrate that SB-509 appears to have not only a neuroprotective but possibly also a neuroregenerative effect. Currently, the only treatment options are analgesics and antidepressants to control pain symptoms. In contrast, SB-509 is designed to address the actual nerve damage and therefore could have a profound impact on the lives of patients suffering with diabetic neuropathy."

In addition, Sangamo announced today t
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Roper Industries, Inc. (NYSE: ROP) ... a definitive agreement to acquire Northern Digital, Inc., ... medical applications.  Northern Digital will become part of ... Ontario, Canada, Northern Digital provides optical and electromagnetic ...
... Conn., May 10, 2011 Biodel Inc. (Nasdaq: ... initiated a pump trial of Biodel,s two ultra-rapid-acting formulations ... BIOD-105 and BIOD-107, are designed to result in more ... analogs.  This study is designed as a double blinded, ...
Cached Medicine Technology:Roper Industries to Acquire Northern Digital, Inc. 2Roper Industries to Acquire Northern Digital, Inc. 3Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps 2Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps 3Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps 4
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Walter and Eliza Hall Institute scientists have revealed ... in the immune system, identifying in the process ... disorders. Dr Jeff Babon and Professor Nick ... and Haematology divisions respectively, study interactions between internal ...
... wallpaper-like liner help reduce the number of cases of malaria, ... Shepard, a professor at the Schneider Institutes for Health Policy ... gotten the Bill and Melinda Gates Foundation to help. A ... allow Shepard and collaborators to pursue their research in Kenya ...
... , THURSDAY, Feb. 16 (HealthDay News) -- Researchers have sequenced ... and the transmissible facial cancer that threatens the species with ... meat-eating marsupials found only on the Australian island of Tasmania, ... the journal Cell . "There are targeted drugs ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers have discovered ... of cases of inherited dilated cardiomyopathy, a serious heart muscle ... In the study, published in the Feb. 16 issue ... analyzed the DNA of 312 people with dilated cardiomyopathy, 231 ...
... parent-training program is effective in reducing the risk of low-income, ... found that after one year, there was a 9 percent ... group, while a control group that did not receive the ... obese children. "This is the first ...
... Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers report ... kicking off puberty in humans, a finding that offers insight ... who suffer from a rare disease that prevents the start ... family whose members have suffered from the disease confirmed that ...
Cached Medicine News:Health News:Cell signaling discovery provides new hope for blood disorders 2Health News:Gates Foundation awards grant to tackle malaria 2Health News:Genome Map Might Help Save Tasmanian Devil From Extinction 2Health News:Study Finds Gene Behind Inherited Cases of Enlarged Heart 2Health News:Study Finds Gene Behind Inherited Cases of Enlarged Heart 3Health News:Parent-training intervention curbs pediatric obesity rates, study shows 2Health News:Parent-training intervention curbs pediatric obesity rates, study shows 3Health News:Gene Linked to Start of Puberty 2
... electrophysiology system is the Espion. This is an ... wide variety of stimulators for different types of ... ,The Espion system was designed from the ... standard clinical visual function tests, ERG, VEP, PERG, ...
... heart of the Espion2 Electrophysiology system. The ... chassis, real-time DSP, USB control, an isolated ... amplifiers. The E2 connects to any Windows ... standard wi-fi Ethernet. The E2 includes easy ...
... II-i series is a wheelchair accessible, computerized ... field. ,By using SITA, the expert operating ... up to 70%. ,A patented aspherically shaped ... increase patient comfort while testing out to ...
... AAA Endoprosthesis is an innovative device designed ... for patients with abdominal aortic aneurysms (AAA). ... bifurcated graft with an outer self-expanding Nitinol ... and material durability. The function of the ...
Medicine Products: